A randomized, double-blind, 4 way cross-over, placebo controlled trial to evaluate the onset of action of bilastine 20 mg vs. placebo, cetirizine 10 mg, and fexofenadine 120 mg in the Vienna challenge chamber
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2012
At a glance
- Drugs Bilastine; Cetirizine; Fexofenadine
- Indications Allergic rhinitis
- Focus Therapeutic Use
- 24 Mar 2009 Actual patient number (75) added as reported by ClinicalTrials.gov.
- 08 Feb 2007 New trial record.